Safety and efficacy of camrelizumab and apatinib in combination with IMRT in unresectable hepatocellular carcinoma: A non-randomised phase 2 study.

被引：0
|
作者：
Wang, Wei-Hu
Xing, Baocai
Wang, Hongzhi
Zhu, Xianggao
Wang, Kun
Zheng, Xuan
Dong, Dezuo
机构：
[1] Peking Univ Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Minist Educ Beijing, Dept Radiat Oncol, Beijing, Peoples R China
[2] Peking Univ Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Dept Hepatopancreatobiliary Surg Unit 1, Minist Educ Beijing, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16157
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Efficacy and safety of the combination of envafolimab and lenvatinib in unresectable hepatocellular carcinoma: a single-arm, multicentre, exploratory phase II clinical study
    Jiang, Yi
    Su, Ke
    Li, Han
    Wang, Chenjie
    Wu, Zhenying
    Chen, Jiali
    Zhang, Zhiyao
    He, Kun
    Han, Yunwei
    INVESTIGATIONAL NEW DRUGS, 2025, 43 (01) : 18 - 29
  • [22] Transarterial chemoembolization combined with camrelizumab and apatinib in the treatment of advanced hepatocellular carcinoma: Preoperative or postoperative combination? A prospective clinical study
    Xie, Hui
    Yang, Yuqing
    Liu, Yane
    Wen, Zhenyu
    Wang, Junxiao
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [23] Efficacy and safety of vitamin K plus sorafenib combination treatment against hepatocellular carcinoma-Open label, randomized, phase 2 study.
    Haruna, Yoshimichi
    Inoue, Atsuo
    HEPATOLOGY, 2017, 66 : 741A - 741A
  • [24] Effectiveness and Safety of Combination Therapy of Transarterial Chemoembolization and Apatinib for Unresectable Hepatocellular Carcinoma in the Chinese Population: A Meta-Analysis
    Wei, Yan
    Liu, Jianjun
    Yan, Min
    Zhao, Shuguang
    Long, Yong
    Zhang, Weilu
    CHEMOTHERAPY, 2019, 64 (02) : 94 - 104
  • [25] Efficacy and safety of camrelizumab combined with apatinib in the treatment of advanced gastric cancer: Preliminary results from a multicenter, prospective study.
    He, Yifu
    Hu, Bing
    Liu, Ke
    Cheng, Xiaofei
    Cheng, Huaidong
    Chen, Mo
    Hu, Changlu
    Li, Chenghui
    Mei, Xinkuan
    Liu, Jianfeng
    Liu, Hu
    Wang, Gang
    Li, Hongxia
    Zhang, Dingqing
    Luo, Huiqin
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [26] Safety and efficacy of transarterial chemoembolization combined with tyrosine kinase inhibitors and camrelizumab in the treatment of patients with advanced unresectable hepatocellular carcinoma
    Li, Jinpeng
    Jia, Yuntao
    Han, Huihui
    Lin, Yanyan
    Song, Jinlong
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [27] Camrelizumab (C) in combination with apatinib (A) in patients with advanced hepatocellular carcinoma (RESCUE): An open-label, multicenter, phase II trial
    Xu, J.
    Shen, J.
    Gu, S.
    Zhang, Y.
    Wu, L.
    Wu, J.
    Shao, G.
    Zhang, Y.
    Xu, L.
    Yin, T.
    Liu, J.
    Ren, Z.
    Xiong, J.
    Mao, X.
    Zhang, L.
    Yang, J.
    Li, L.
    Chen, X.
    Wang, Z.
    Wang, Q.
    ANNALS OF ONCOLOGY, 2020, 31 : S689 - S689
  • [28] Safety and efficacy of transarterial chemoembolization combined with tyrosine kinase inhibitors and camrelizumab in the treatment of patients with advanced unresectable hepatocellular carcinoma
    Li, Jinpeng
    Kong, Mingxin
    Yu, Guangji
    Wang, Song
    Shi, Zhaozhang
    Han, Huihui
    Lin, Yanyan
    Shi, Jutian
    Song, Jinlong
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [29] Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial
    Xia, Yongxiang
    Tang, Weiwei
    Qian, Xiaofeng
    Li, Xiangcheng
    Cheng, Feng
    Wang, Ke
    Zhang, Feng
    Zhang, Chuanyong
    Li, Donghua
    Song, Jinhua
    Zhang, Hui
    Zhao, Jie
    Yao, Aihua
    Wu, Xiaofeng
    Wu, Chen
    Ji, Guwei
    Liu, Xisheng
    Zhu, Feipeng
    Qin, Lang
    Xiao, Xuan
    Deng, Zhenhua
    Kong, Xiangyi
    Li, Si
    Yu, Yangyang
    Xi, Wenjing
    Deng, Wanglong
    Qi, Chuang
    Liu, Hanyuan
    Pu, Liyong
    Wang, Ping
    Wang, Xuehao
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (04)
  • [30] The safety and efficacy of TACE combined with apatinib on patients with advanced hepatocellular carcinoma: a retrospective study
    Yang, Zeran
    Chen, Guang
    Cui, Ye
    Xiao, Guowen
    Su, Tianhao
    Yu, Jianan
    Zhang, Zhiyuan
    Han, Yanjing
    Yang, Kailan
    Jin, Long
    CANCER BIOLOGY & THERAPY, 2019, 20 (03) : 321 - 327
12345